Young L S
Rev Infect Dis. 1985 Jul-Aug;7 Suppl 3:S380-8. doi: 10.1093/clinids/7.supplement_3.s380.
Failure of therapy for microbial infections may be related to a number of factors, a major one being drug resistance. Although much progress has been made during the past decade, agents are still needed for improved treatment of infections in which clinical success rates remain unsatisfactory. Problem pathogens include enteric bacteria such as Serratia species, Enterobacter species, and a number of nonfermenting gram-negative bacilli, including Pseudomonas species. Gram-positive organisms that continue to pose a significant therapeutic problem are the coagulase-positive and coagulase-negative staphylococci and enterococci. Atypical mycobacterial species offer major therapeutic challenges. No important broad-spectrum antifungal agents of low toxicity have been developed during the past two decades. Any new antibacterial or antifungal agent should be potent, safe, and well tolerated and should possess pharmacokinetic advantages that will lead to more simplified dosing; low cost would be an additional important advantage.
微生物感染治疗失败可能与多种因素有关，其中一个主要因素是耐药性。尽管在过去十年中已经取得了很大进展，但对于临床成功率仍不尽人意的感染，仍需要有更好的治疗药物。问题病原体包括肠道细菌，如沙雷氏菌属、肠杆菌属，以及一些非发酵革兰氏阴性杆菌，包括假单胞菌属。继续构成重大治疗难题的革兰氏阳性菌是凝固酶阳性和凝固酶阴性葡萄球菌以及肠球菌。非典型分枝杆菌也带来了重大的治疗挑战。在过去二十年中，尚未研发出重要的低毒性广谱抗真菌药物。任何新的抗菌或抗真菌药物都应强效、安全且耐受性良好，并应具有药代动力学优势，从而使给药更简便；低成本将是另一个重要优势。
